At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
atorvastatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Implications for Treatment of the Metabolic Syndrome
University Hospital Southampton NHS Foundation Trust·interventional·Posted Apr 24, 2008·Updated Jan 23, 2019
In Brief
A Phase 2 clinical trial evaluating atorvastatin and placebo for Metabolic Syndrome. Completed, enrolled 40 participants.
Detailed Summary
To characterize features of metabolic syndrome in volunteers. To undertake a randomised trial to determine whether treatment with a statin improves muscle microvascular blood flow.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
Primary CompletionFeb 2008
First PostedApr 2008
TodayJul 2026
First PostedApr 24, 2008
Enrollment StartFeb 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.2 years ago
Interventions
atorvastatindrug
40 m.g. o.d. tablets for 6 months
placebodrug
Placebo